Tablets 5 mg
ATC A10B B01
Prescription-only medicine
Medicine reimburse by Health Insurance Fund


The dosage of glibenclamide is governed by the desired blood glucose level.

The dosage of glibenclamide must be the lowest possible dose which is effective.

Mistakes, e.g. forgetting to take a dose, must never be corrected by subsequently taking a larger dose.

The usual total daily dosage is 2.5 mg to 15 mg daily with a usual initial dose of 5 mg daily. Weekly adjustments can be made to increase the dosage to the optimal level. Doses of 10 mg or less may be taken as a single dose immediately before breakfast, but should the daily dose exceed 10 mg, the remainder should be taken immediately before the evening meal.

The elderly usually require a lower dosage.

Dose Omission

A physician should be consulted in the event that a dose has not been taken at the prescribed time, a meal has been skipped or an extra dose has been taken. It is very important not to skip meals after the tablets have been taken.

Secondary Dosage Adjustment

As an improvement in control of diabetes is, in itself, associated with higher insulin sensitivity, glibenclamide requirements may fall as treatment proceeds. To avoid hypoglycemia, timely dose reduction or cessation of glibenclamide therapy must, therefore, be considered. Correction of dosage must also be considered, whenever: – the patient’s weight changes, – the patient’s lifestyle changes, – other factors arise, which cause increased susceptibility to hypoglycemia or hyperglycemia.

Medicine’s information on this web page is only a short description of its characteristics. Do not take them as recommendations for self-treatment of your health condition.

You must inform your physician and pharmacist and follow their recommendations before you use the medicine for treatment. Always read carefully the patient information leaflet.


Each tablet contains 5 mg glibenclamide, excipiens.


Glibenclamide is a sulphonylurea hypoglycaemic agent, indicated for the oral treatment of patients with non-insulin dependent diabetes who respond inadequately to dietary measures alone.


Glibenclamide should not be used in patients who have or have ever had diabetic ketoacidosis or diabetic coma/precoma or in patients who have insulin-dependent diabetes mellitus, serious impairment of renal, hepatic or adrenocortical function, in patients who are hypersensitive to glibenclamide or any of the excipients, or in circumstances of unusual stress, e.g. surgical operations or during pregnancy, when dietary measures and insulin are essential. Glibenclamide should not be used in the following groups: – patients with sulphonylurea or sulphonamide intolerance, – patients with juvenile diabetes, – pregnancy, – breastfeeding women, – children, – in patients treated with bosentan.


Box with 40 tablets of 5 mg (4 blisters x 10 tablets)